logo

Articles scientifiques (5 dernières années)

Google Scholar
Global impact and cost‑effectiveness of one‑dose versus two‑dose human papillomavirus vaccination schedules: a comparative modelling analysis BMC Med 2023;21(313). https://doi.org/10.1186/s12916-023-02988-3 Prem K, Choi YH, Bénard É, Burger EA, Hadley L, Laprise JF, Regan MC, Drolet M, Sy S, Abbas K, Portnoy A, Kim JJ, Brisson M, Jit M
Regional and country-level trends in cervical cancer screening coverage in sub-Saharan Africa: A systematic analysis of population-based surveys (2000–2020) PLoS medicine 2023;20(1):e1004143 Yang L, Boily MC, Rönn MM, Obiri-Yeboah D, Morhason-Bello I, Meda N, Lompo O, Mayaud P, Pickles M, Brisson M, Hodgins C, Delany-Moretlwe S, Maheu-Giroux M
Potential benefit of extended dose schedules of human papillomavirus vaccination in the context of scarce resources and COVID-19 disruptions in low-income and middle-income countries: a mathematical modelling analysis Lancet Global Health 2023;11(1):e48-58. Bénard E, Drolet M, Laprise JF, Jit M, Prem K, Boily MC, Brisson M
Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study The Lancet ID 2023;23(1):45-55. https://doi.org/10.1016/S1473-3099(22)00578-3. Carazo S, Skowronski DM, Brisson M, Barkati S, Sauvageau C, Brousseau N, Gilca R, Fafard J, Talbot D, Ouakki M, Gilca V, Carignan A, Deceuninck G, De Wals P, De Serres G
Estimating the effect of HIV on cervical cancer elimination in South Africa: Comparative modelling of the impact of vaccination and screening eClinicalMedicine 2022, Nov. 17;101754 https://doi.org/10.1016/j.eclinm.2022.101754 Boily MC, Barnabas RV, Rönn MM, Bayer CJ, Schalkwyk C, Sonia N, Rao DW, Staadegaard L, Liu G, Silhol R, Brisson M, Johnson LF, Bloem P, Gottlieb S, Broutet N, Dalal S
Two-Dose Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Effectiveness With Mixed Schedules and Extended Dosing Intervals: Test-Negative Design Studies From British Columbia and Quebec, Canada Clinical Infectious Diseases 2022;75(11):1980–1992 Skowronski DM, Febriani Y, Ouakki M, Setayeshgar S, El Adam S, Zou M, Talbot D, Prystajecky N, Tyson JR, Gilca R, Brousseau N, Deceuninck G, Galanis E, Fjell CD, Sbihi H, Fortin E, Barkati S, Sauvageau C, Naus M, Patrick DM, Henry B, Hoang LMN, De Wals P, Garenc C, Carignan A, Drolet M, Jassem AN, Sadarangani M, Brisson M, Krajden M, De Serres G
Prevalence and risk factors for human papillomavirus infection among female sex workers in Hanoi and Ho Chi Minh City, Viet Nam: a cross-sectional study – Prevalence and risk factors for HPV among FSWs in Viet Nam Western Pac Surveill Response J 2022;13(4):1-11. doi: 10.5365/wpsar.2022.13.4.894 Pham QD, Prem K, Le TA, Trang NV, Jit M, Nguyen TA, Cao V, Le-Ha TD, Chu MTN, Le LTK, Toh ZQ, Brisson M, Garland S, Murray G, Bright K, Dang DA, Tran HP, Mulholland EK
Immunogenicity, safety, and efficacy of the HPV vaccines among people living with HIV: A systematic review and meta-analysis eClinicalMedicine 2022;52:101585 https://doi.org/10.1016/j.eclinm.2022.101585 Staadegaard L, Rönn MM, Soni N, Bellerose ME, Bloem P, Brisson M, Maheu-Giroux M, Barnabas RV, Drolet M, Mayaud P, Dalal S, Boily MC
Estimated Protection of Prior SARS-CoV-2 Infection Against Reinfection With the Omicron Variant Among Messenger RNA–Vaccinated and Nonvaccinated Individuals in Quebec, Canada JAMA Netw Open. 2022;5(10):e2236670. doi:10.1001/jamanetworkopen.2022.36670 Carazo S, Skowronski DM, Brisson, M
Letter to the Editor: Recent economic evaluation of 1-dose HPV vaccination uses unsupported assumptions Vaccine 2022 https://doi.org/10.1016/j.vaccine.2022.07.022 Burger E, Baussano I, Kim JJ, Laprise JF, Berkhof J, Schiller JT, Canfell K, Prem K, Brisson M, Jit M, Barnabas RV
Human papillomavirus vaccine effectiveness by number of doses: Updated systematic review of data from national immunization programs Vaccine 2022;S0264-410X(22)00834-9. doi: 10.1016/j.vaccine.2022.06.065. Online ahead of print. Markowitz LE, Drolet M, Lewis RM, Lemieux-Mellouki P, Pérez N, Jit M, Brotherton JM, Ogilvie, G Kreimer AR, Brisson M
Review of the current published evidence on single-dose HPV vaccination 4th Edition PATH. May 2022. Single dose HPV vaccine evaluation consortium
Time trends in social contacts of individuals according to comorbidity and vaccination status, before and during the COVID-19 pandemic BMC Medicine (2022) 20:199. https://doi.org/10.1186/s12916-022-02398-x Godbout A, Drolet M, Mondor M, Simard M, Sauvageau C, De Serres G, Brisson M
Time trends in social contacts before and during the COVID-19 pandemic: the CONNECT study BMC Public Health 2022;22:1032. https://doi.org/10.1186/s12889-022-13402-7 Drolet M, Godbout A, Mondor M, Béraud G, Drolet-Roy L, Lemieux-Mellouki P, Bureau A, Demers É, Boily MC, Sauvageau C, De Serres G, Hens N, Beutels P, Dervaux B, Brisson M
Now or later: Health impacts of delaying single-dose HPV vaccine implementation in a high-burden setting Int J Cancer 2022. doi:10.1002/ijc.34054. Online ahead of print. Burger EA, Laprise JF, Sy S, Regan MC, Prem K, Jit M, Brisson M, Kim JJ
Mortality trends and length of stays among hospitalized patients with COVID-19 in Ontario and Québec (Canada): a population-based cohort study of the first three epidemic waves Int J Infect Dis 2022;121:1-10. doi:10.1016/j.ijid.2022.04.048. Online ahead of print Xia Y, Ma H, Buckeridge DL, Brisson M, Sander B, Chan A, Verma A, Ganser I, Kronfli N, Mishra S, Maheu-Giroux M
Population immunity to measles in Canada using Canadian Health Measures survey data – A Canadian Immunization Research Network (CIRN) study Vaccine 2022;40(23):3228-35. doi: 10.1016/j.vaccine.2022.04.011. Epub 2022 Apr 28 Osman S, Crowcroft N, McLachlan E, Hatchette T, Pere-Iratxeta C, Joh E, Wright J, Halperin SA, Deeks S, Wilson S, Buchan S, Ward B, Gubbay J, Brisson M, Serhir B, Severini A, Bolotin S
Single-dose mRNA vaccine effectiveness against SARS-CoV-2 in healthcare workers extending 16 weeks post-vaccination: a test-negative design from Quebec, Canada Clin Infect Dis . 2021 Aug 30;ciab739. doi: 10.1093/cid/ciab739. Online ahead of print Carazo S, Talbot D, Boulianne N, Brisson M, Gilca R, Deceuninck G, Brousseau N, Drolet M, Ouakki M, Sauvageau C, Barkati S, Fortin E, Carignan A, De Wals P, Skowronski DM, De Serres G
Potential Benefit of Extended Dose Schedules of Human Papillomavirus (HPV) Vaccination in the Context of Limited Resources and COVID-19 Disruptions in Low- and Middle-Income Countries: A Mathematical Modeling Analysis. Preprint available at SSRN 4016646, 2021 Bénard E, Drolet M, Laprise JF, Jit M, Prem K, Boily MC, Brisson MC
Geographic concentration of SARS-CoV-2 cases by social determinants of health in metropolitan areas in Canada: a cross-sectional study CMAJ 2022;194(6):E195-E204. doi: 10.1503/cmaj.211249 Xia Y, Ma H, Moloney G, Velásquez García HA, Sirski M, Janjua NZ, Vickers D, Williamson T, Katz A, Yiu K, Kustra R, Buckeridge DL, Brisson M, Baral SD, Mishra S, Maheu-Giroux M
Anal human papillomavirus prevalence and risk factors among men who have sex with men in Vietnam Int J Infect Dis . 2021 Nov;112:136-143. doi: 10.1016/j.ijid.2021.09.016 Tuan LA, Prem K, Pham QD, Toh ZQ, Tran HP, Nguyen PD, Mai CTN, Ly LTK, Cao V, Le-Ha TD, Tuan NA, Jit M, Bright K, Brisson M, Nguyen TV, Garland S, Anh DD, Trang NV, Mulholland K
Time trends in social contacts before and during the COVID-19 pandemic: the CONNECT study MedRxiv doi: https://doi.org/10.1101/2021.10.06.21264632 Drolet M, Godbout A, Mondor M, Drolet-Roy L, Beraud G, Lemmieux-Mellouki P, Demers E, Boily MC, Sauvageau C, De Serres G, Hens N, Beutels P, Dervaux B, Brisson M
Optimal human papillomavirus vaccination strategies to prevent cervical cancer in low-income and middle-income countries in the context of limited resources: a mathematical modelling analysis Lancet Infect Dis 2021. doi: https://doi.org/10.1016/S1473-3099(20)30860-4 Drolet M, Laprise JF, Martin D, Jit M, Bénard É, Gingras G, Boily MC, Alary M, Baussano I, Hutubessy R, Brisson M
Assessing fitness-for-purpose and comparing the suitability of COVID-19 multi-country models for local contexts and users Gates Open Research 2021;5(79):79 Clapham H, Gad M, Gheorghe A, Hutubessy R, Megiddo I, Painter C, Ruiz F, Cheikh N, Gorgens M, Wilkinson T, Brisson M, Gay N, Labadin J, McVernon J, Luz PM, Ndifon W, Nichols BE, Prinja S, Salomon J, Tshangela A
Human papillomavirus (HPV) vaccine uptake among a community-recruited sample of gay, bisexual, and other men who have sex with men in the three largest cities in Canada from 2017 to 2019 Vaccine. 2021;39(28):3756-3766. doi: 10.1016/j.vaccine.2021.05.031. Epub 2021 May 29. Grewal R, Deeks SL, Hart TA, Coxh J, De Pokomandy A, Grennan T, Lambert G, Moore D, Brisson M, Coutlée F, Gaspar M, George C, Grace D, Jollimore J, Lachowsky NJ, Nisenbauma R, Ogilvie G, Sauvageau C, Burchell AN
From cervical cancer elimination to eradication of vaccine-type human papillomavirus: Feasibility, public health strategies and cost-effectiveness Prev Med. 2021;144:106354 Jit M, Prem K, Benard E, Brisson M
The Estimated Lifetime Medical Cost of Diseases Attributable to Human Papillomavirus Infections Acquired in 2018 Sex Transm Dis. 2021 Apr 1;48(4):278-284 Chesson HW, Laprise JF, Brisson M, Martin D, Ekwueme DU, Markowitz LE.
Global impact and cost-effectiveness of one-dose versus two-dose human papillomavirus vaccination schedules: a comparative modelling analysis MedRxiv Prem K, Choi YH, Bénard E, Burger EA, Hadley L, Laprise JF, Regan C, Drolet M, Sy S, Abbas K, Kim JJ, Brisson M, Jit M
The role of case importation in explaining differences in early SARS-CoV-2 transmission dynamics in Canada – A mathematical modeling study of surveillance data Int J Inf Dis 2021;102:254-9. doi: 10.1016/j.ijid.2020.10.046 Godin A, Xia Y, Buckeridge DL, Mishra S, Douwes-Schultz D, Shen Y, Lavigne M, Drolet M, Schmidt AM, Brisson M, Maheu-Giroux M
Estimated prevalence and incidence of disease-associated HPV types among 15-59-year-olds in the United States Sex Transm Dis 2021; Volume Publish Ahead of Print - doi: 10.1097/OLQ.0000000000001356 Lewis RM, Laprise JF, Gargano JW, Unger ER, Querec TD, Chesson H, Brisson M, Markowitz LE
Estimating the health impact of vaccination against ten pathogens in 98 low-income and middle-income countries from 2000 to 2030: a modelling study The Lancet 2021;397(10272):398-408. doi: 10.1016/S0140-6736(20)32657-X Li X, Mukandavire C, Cucunubá ZM, Londono SE, Abbas K, Clapham HE, Jit M, Johnson HL, Papadopoulos T, Vynnycky E, Brisson M, et al.
Epidemiology of varicella among immigrants and non-immigrants in Quebec, Canada, before and after the introduction of childhood varicella vaccination: a retrospective cohort study Lancet Infect Dis 2021;21(1):116-126. doi: 10.1016/S1473-3099(20)30277-2 Greenaway C, Greenwald ZR, Akaberi A, Song S, Passos-Castilho AM, Chakra CNA, Palayew A, Alabdulkarim B, Platt R, Azoulay L, Brisson M, Quach C
The Estimated Direct Lifetime Medical Costs of Sexually Transmitted Infections Acquired in the United States in 2018 Sexually Transmitted Diseases 2021;;48(4):215-21 Chesson HW, Spicknall IH, Bingham A, Brisson M, Eppink ST, Farnham PG, Kreisel KM, Kumar S, Laprise JF, Peterman TA, Roberts H, Gift TL
Continued HPV vaccination in the face of unexpected challenges: A commentary on the rationale for an extended interval two-dose schedule Vaccine. Available online 13 January 2021. https://doi.org/10.1016/j.vaccine.2020.12.031 Whitworth HS, Schiller J, Markowitz LE, Jit M, Brisson M, Simpson E, Watson-Jones D
Mortality reductions and lives saved on the path to eliminating cervical cancer in 78 Low and Lower-Middle Income Countries: Comparative modelling of impact of achieving WHO targets for scaling up vaccination, cervical screening and cancer treatment services The Lancet 2020. https://doi.org/10.1016/S0140-6736(20)30157-4 Canfell K, Kim J, Brisson M, Keane A, Simms K, Caruana M, Burger E, Martin D, Nguyen DTN, Benard É, Sy S, Regan C, Laprise JF, Torode J, Smith M, Fidarova E, Trapani D, Ilbawi A, Broutet N, Hutubessy R
Impact of HPV vaccination and cervical screening on cervical cancer elimination: a comparative modelling analysis in 78 low-income and lower-middle-income countries. The Lancet 2020. https://doi.org/10.1016/S0140-6736(20)30068-4 Brisson M, Kim JJ, Canfell K, Drolet M, Gingras G, Burger EA, Martin D, Simms KT, Bénard É, Boily MC, Sy S, Regan C, Keane A, Caruana M, Nguyen DTN, Smith MA, Laprise JF, Jit M, Alary M, Bray F, Fidarova E, Elsheikh F, Bloem PJN, Broutet N, Hutubessy R.
Effects of updated demography, disability weights, and cervical cancer burden on estimates of human papillomavirus vaccination impact at the global, regional, and national levels: a PRIME modelling study Lancet Glob Health 2020. doi: 10.1016/S2214-109X(20)30022-X. [Epub ahead of print] Abbas KM, van Zandvoort K, Brisson M, Jit M
Review of the current published evidence for single-dose HPV vaccination: White Paper RHO Cervical Cancer Library Single-Dose HPV Vaccine Evaluation Consortium
Modelling multi-site transmission of the human papillomavirus and its impact on vaccination effectiveness Lemieux-Mellouki P, Drolet M, Jit M, Gingras G, Brisson M Epidemics 2017Dec;21:80-87. doi: 10.1016/j.epidem.2017.08.001.
Review of the current published evidence for single-dose HPV vaccination 2nd Edition: White Paper RHO Cervical Cancer Library Single-Dose HPV Vaccine Evaluation Consortium
Population-level impact and herd effects following the introduction of human papillomavirus vaccination programmes: updated systematic review and meta-analysis The Lancet 2019;DOI: https://doi.org/10.1016/S0140-6736(19)30298-3 Drolet M, Bénard E, Pérez N, Brisson M, the HPV Vaccination Impact Study Group
Assessment of population immunity to measles in Ontario, Canada: a Canadian Immunization Research Network (CIRN) study Hum Vaccin Immunother. 2019 Jul 16:1-9. doi: 10.1080/21645515.2019.1619402 Bolotin S, Severini A, Hatchette T, McLachlan E, Savage R, Hughes SL, Wang J, Deeks SL, Wilson S, Brisson M, Halperin SA, Gubbay J, Mazzulli T, Serhir B, Ward BJ, Crowcroft N
An online decision tree for vaccine efficacy trial design during infectious disease epidemics: The InterVax-Tool Vaccine. 2019 Jul 18;37(31):4376-4381. doi: 10.1016/j.vaccine.2019.06.019. Epub 2019 Jun 24 Bellan SE, Eggo RM, Gsell PS, Kucharski AJ, Dean NE, Donohue R, Zook M, Edmunds WJ, Odhiambo F, Longini IM Jr, Brisson M, Mahon BE, Henao-Restrepo AM
Guidelines for multi-model comparisons of the impact of infectious disease interventions BMC Med. 2019 Aug 19;17(1):163. doi: 10.1186/s12916-019-1403-9 den Boon S, Jit M, Brisson M, Medley G, Beutels P, White R, Flasche S, Hollingsworth TD, Garske T, Pitzer VE, Hoogendoorn M, Geffen O, Clark A, Kim J, Hutubessy R
Effectiveness and cost-effectiveness of vaccination against herpes zoster in Canada: a modelling study CMAJ August 26, 2019 191 (34) E932-E939; DOI: https://doi.org/10.1503/cmaj.190274 Drolet M, Zhou Z, Sauvageau C, DeWals P, Gilca V, Amini R, Bénard É, Brisson M
HPV-FRAME: A consensus statement and quality framework for modelled evaluations of HPV-related cancer control Papillomavirus research, ISSN: 2405-8521, Vol: 8 (2019), Page: 100184 Canfell K, Kim JJ, Kulasingam S, Berkhof J, Barnabas R, Bogaards JA, Campos N, Jennett C, Sharma M, Simms KT, Smith MA, Velentzis LS, Brisson M, Jit M
Effectiveness and Cost-Effectiveness of Human Papillomavirus Vaccination Through Age 45 Years in the United States Ann Intern Med. 2019 Dec 10. doi: 10.7326/M19-1182. [Epub ahead of print] Laprise JF, Chesson HW, Markowitz LE, Drolet M, Martin D, Bénard É, Brisson M.
Global elimination of cervical cancer as a public health problem The Lancet Oncology 2019 Mar;20(3):319-321. doi: 10.1016/S1470-2045(19)30072-5. Brisson M, Drolet M
Potential lives saved in 73 countries by adopting multi-cohort vaccination of 9-14 year old girls against human papillomavirus Int J Cancer. 2018 Jul 15;143(2):317-323. doi: 10.1002/ijc.31321. Jit M, Brisson M
Human papillomavirus vaccine effectiveness by number of doses: Systematic review of data from national immunization programs Vaccine 2018 Aug;36(32A):4806-15. doi.org/10.1016/j.vaccine.2018.01.057 Markowitz LE, Drolet M, Perez N, Jit M, Brisson M
Evidence of synergistic relationships between HIV and Human Papillomavirus (HPV): systematic reviews and meta-analyses of longitudinal studies of HPV acquisition and clearance by HIV status, and of HIV acquisition by HPV status. J Int AIDS Soc. 2018 Jun;21(6):e25110. doi: 10.1002/jia2.25110 Looker KJ, Rönn MM, Brock PM, Brisson M, Drolet M, Mayaud P, Boily MC.
Model Comparisons of the Effectiveness and Cost-effectiveness of Vaccination: A Systematic Review of the Literature Value in Health 2018 Oct; 21(10):1250-58. doi.org/10.1016/j.jval.2018.03.014 Drolet D, Bénard É, Jit M, Hutubessy R, Brisson M
The impact of human papillomavirus catch-up vaccination in Australia: Implications for introduction of multiple age cohort vaccination and post-vaccination data interpretation J Infect Dis 2017Dec5;216(10):1205-09. doi: 10.1093/infdis/jix476. Drolet M, Laprise JF, Brotherton JML, Donovan B, Fairley CK, Ali H, Bénard É, Martin D, Brisson M
Can high overall human papillomavirus vaccination coverage hide sociodemographic inequalities? An ecological analysis in Canada Vaccine. 2016Apr7;34(16):1874-80. doi: 10.1016/j.vaccine.2016.02.069. Drolet M, Deeks SL, Kliewer E, Musto G, Lambert P, Brisson M
Comparison of 2-Dose and 3-Dose 9-Valent Human Papillomavirus Vaccine Schedules in the United States: A Cost-effectiveness Analysis. J Infect Dis. 2016Sep1;214(5):685-8. doi: 10.1093/infdis/jiw227 Laprise JF, Markowitz LE, Chesson HW, Drolet M, Brisson M
Mathematical Modeling of the Transmission Dynamics of Clostridium difficile Infection and Colonization in Healthcare Settings: A Systematic Review. PLoS One. 2016;11(9):e0163880. doi: 10.1371/journal.pone.0163880. Gingras G, Guertin MH, Laprise JF, Drolet M, Brisson M
Effect of HPV on cervical cancer screening in Alberta. CMAJ. 2016;188(14):1035. Brisson M, Drolet M, Bénard É, Kreimer AR
Population-Level Effects of Human Papillomavirus Vaccination Programs on Infections with Nonvaccine Genotypes. Emerg Infect Dis. 2016;22(10):1732-40. doi: 10.3201/eid2210.160675. Mesher D, Soldan K, Lehtinen M, Beddows S, Brisson M, Brotherton JM, Chow EP, Cummings T, Drolet M, Fairley CK, Garland SM, Kahn JA, Kavanagh K, Markowitz L, Pollock KG, Söderlund-Strand A, Sonnenberg P, Tabrizi SN, Tanton C, Unger E, Thomas SL
Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis Lancet Pub Health 2016;1(2):e66-75 Simms KT, Laprise JF, Smith MA, Lew JB, Caruana M, Brisson M, Canfell K
Population-level impact, herd immunity, and elimination after human papillomavirus vaccination: a systematic review and meta-analysis of predictions from transmission-dynamic models Lancet Pub Health 2016;1(1):e8-17 Brisson M, Bénard É, Drolet M, Bogaards JA, Baussano I, Vänskä S, Jit M, Boily MC, Smith MA, Berkhof J, Canfell K, Chesson HW, Burger EA, Choi YH, De Blasio BF, De Vlas SJ, Guzzetta G, Hontelez JAC, Horn J, Jepsen MR, Kim JJ, Lazzarato F, Matthijsse SM, Mikolajczyk R, Pavelyev A, Pillsbury M, Shafer LA, Tully SP, Turner HC, Usher C, Walsh C
Bias Due to Correlation Between Times-at-Risk for Infection in Epidemiologic Studies Measuring Biological Interactions Between Sexually Transmitted Infections: A Case Study Using Human Papillomavirus Type Interactions Am J Epidemiol. 2016 15;184(12):873-883 Malagón T, Lemieux-Mellouki P, Laprise JF, Brisson M
Eurogin Roadmap 2015: How has HPV knowledge changed our practice: vaccines Int J Cancer. 2016Aug1;139(3):510-17. doi: 10.1002/ijc.30063 Brotherton JML, Jit M, Gravitt PE, Brisson M, Kreimer AR, Pai SI, Fakhry C, Monsonego J, Franceschi S
The Impact and Cost-Effectiveness of 3 doses of 9-Valent Human Papillomavirus (HPV) Vaccine among US Females Previously Vaccinated with 4-Valent HPV Vaccine J Infect Dis. 2016Jun1;213(11):1694-1700. doi: 10.1093/infdis/jiw046 HW Chesson, JF Laprise, M Brisson, LE Markowitz
Human Papillomavirus Vaccination at a Time of Changing Sexual Behavior Emerg Infect Dis. 2016;22(1):18-23. doi: 10.3201/eid2201.150791 Baussano I, Lazzarato F, Brisson M, Franceschi S
Assortative mixing as a source of bias in epidemiological studies of sexually transmitted infections: the case of smoking and human papillomavirus. Epidemiol Infect. 2016 May;144(7):1490-9. doi: 10.1017/S0950268815002915. Lemieux-Mellouki P, Drolet M, Brisson J, Franco EL, Boily MC, Baussano I, Brisson M
Health and Economic Impact of Switching from a 4-Valent to a 9-Valent HPV Vaccination Program in the United States JNCI J Natl Cancer Inst. 2016;108(1) doi: 10.1093/jnci/djv282 Brisson M, Laprise JF, Chesson HW, Drolet M, Malagón T, Boily MC, Markowitz LE